腹膜透析置管患者预防性应用抗生素的研究进展

doi:10.3969/j.issn.1004-583X.2021.12.017

临床荟萃 ›› 2021, Vol. 36 ›› Issue (12): 1136-1138.doi: 10.3969/j.issn.1004-583X.2021.12.017

腹膜透析置管患者预防性应用抗生素的研究进展

路国贤^1a, 刘宇^1b, 刘孜卓²()

1.天津中医药大学第二附属医院 a.内分泌科;b.肾病科,天津 300250
2.天津医科大学总医院急诊医学科,天津 300052

收稿日期:2020-09-15 出版日期:2021-12-20 发布日期:2021-12-24
通讯作者: 刘孜卓 E-mail:49706340@qq.com
基金资助:
天津市卫生和计划生育委员会中医中西医结合课题项目—枯芩对慢性肾衰竭模型微炎症状态的干预作用(20171111)

Received:2020-09-15 Online:2021-12-20 Published:2021-12-24

摘要/Abstract

摘要：

腹膜透析(peritoneal dialysis, PD)是终末期肾病的主要替代治疗之一,但由于腹膜炎、导管出口部位感染和隧道感染等并发症,使PD的发展受到限制。PD置管后感染受多种因素影响,致病菌沿PD管路进入腹腔是最常见原因,以革兰阳性菌最多见。革兰阴性菌选择三代头孢菌素或氨基糖苷类,革兰阳性菌选择一代头孢菌素或万古霉素。本文详述了国内外PD置管患者预防性应用抗生素治疗现状,旨在为临床治疗提供理论依据。

关键词: 腹膜透析, 头孢唑林, 庆大霉素类, 万古霉素, 莫匹罗星

中图分类号:

R459.5

路国贤, 刘宇, 刘孜卓. 腹膜透析置管患者预防性应用抗生素的研究进展[J]. 临床荟萃, 2021, 36(12): 1136-1138.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.12.017

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I12/1136

参考文献 27

[1]	Krediet RT. Peritoneal dialysis: From bench to bedside[J]. Clin Kidney J, 2013, 6(6):568-577. doi: 10.1093/ckj/sft122 URL
[2]	Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis[J]. Nat Rev Nephrol, 2017, 13(2):90-103. doi: 10.1038/nrneph.2016.181 URL
[3]	Morton RL, Tong A, Webster AC, et al. Characteristics of dialysis important to patients and family caregivers: A mixed methods approach[J]. Nephrol Dial Transplant, 2011, 26(12):4038-4046. doi: 10.1093/ndt/gfr177 URL
[4]	Campbell D, Mudge DW, Craig JC, et al. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients[J]. Cochrane Database Syst Rev, 2017, 4(6): CD004679.
[5]	Morton RL, Tong A, Webster AC, et al. Characteristics of dialysis important to patients and family caregivers: A mixed methods approach[J]. Nephrol Dial Transplant, 2011, 26(12):4038-4046. doi: 10.1093/ndt/gfr177 URL
[6]	Heal J. Underutilization of peritoneal dialysis[J]. JAMA, 2004, 291(6):740-742. doi: 10.1001/jama.291.6.740 URL
[7]	Annigeri R, Conly J, Vas S, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection[J]. PeTit Dial Int, 2001, 21(6):554-559.
[8]	Kotsanas D, Polkinghorne KR, Korman TM, et al. Risk factors for peritoneal dialysis-related peritonitis: Can we reduce the incidence and improve patient selection?[J]. Nephrology (Carlton), 2007, 12(3):239-245. doi: 10.1111/nep.2007.12.issue-3 URL
[9]	Martin LC, Caramori JC, Femandes N, et al. Geographic and educational factors and risk of the first peritonitis episode in Brazilian Peritoneal Dialysis study(BRAZPD)patients[J]. Clin J Am Soc Nephrol, 2011, 6(8):1944-1951. doi: 10.2215/CJN.11431210 URL
[10]	余学清. 腹膜透析治疗学[M]. 北京: 科学技术文献出版社, 2008:144-156.
[11]	熊子波, 杨虹, 廖玉梅, 等. 腹膜透析相关性腹膜炎169例次临床分析及转归[J]. 临床肾脏病杂志, 2012, 12(2):63-66.
[12]	Al-Allak A, Jones R, Stiff R, et al. Long-term outcome of continuous ambulatory peritoneal dialysis (CAPD)peritonitis: Surgery can be avoided[J]. Ann R Coll Surg Engl, 2009, 91(2):118-122. doi: 10.1308/003588409X359088 URL
[13]	Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update[J]. Petit Dial Int, 2005, 25(2):107-131.
[14]	Australia K. CARI Guidelines(Caring for Australians with Renal mpairment)[J]. Nephrology (Carlton), 2005, 9(Suppl 3):S1-106. doi: 10.1111/nep.2004.9.issue-s3 URL
[15]	Parsons DP. Preoperative evaluation and risk management[J]. Clin Colon Rectal Surg, 2009, 22(1):5-13. doi: 10.1055/s-0029-1202870 URL
[16]	Zhang L, Badve SV, Pascoe EM, et al. The effect of exit-site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes of peritoneal dialysis-associated peritonitis and exit-site infections: A sub-study of the honeypot trial[J]. Perit Dial Int, 2015, 35(7):712-721. doi: 10.3747/pdi.2014.00206 URL
[17]	Walker A, Bannister K, George C, et al. KHA-CARI Guideline: Peritonitis treatment and prophylaxis[J]. Nephrology(Carlton), 2014, 19(2):69-71.
[18]	Bennett-Jones, Ludwig KA, Fisk MA, et al. Prophylactic antibiotics in surgery[J]. Anna Rev Med, 2019, 44(6):385-393.
[19]	Wikdahl AM, Engman U, Stegmayr BG, et al. One-dose cefuroxime i.v. and i.p.reduces microbial growth in PD patients after catheter insertion[J]. Nephrol Dial Transplant, 1997, 12(1):157-160. doi: 10.1093/ndt/12.1.157 URL
[20]	Gadallah MF, Ramdeen G, Mignone J, et al. Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters[J]. Am J Kidney Dis, 2000, 36(5):1014-1019. pmid: 11054359
[21]	Campbell D, Mudge DW, Craig JC, et al. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients[J]. Cochrane Database Syst Rev, 2017, 4(4):CD004679.
[22]	Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters[J]. Scand J Urol Nephrol, 1992, 26(2):177-180. pmid: 1626207
[23]	陈崴, 姜宗培, 郑勋华, 等. 腹膜透析置管术预防性抗生素用药的前瞻性随机对照临床研究[J]. 中华肾脏病杂志, 2006(10):601-604.
[24]	郑佳麒, 熊子波, 熊祖应, 等. 不同抗生素用药方案在预防腹膜透析置管术后腹膜炎中的比较[J]. 中国血液净化, 2013, 12(8):415-418.
[25]	刘红梅, 姚强, 杨玉红, 等. 腹腔预防性应用抗生素对腹膜透析置管术后发生腹膜炎的临床探讨[J]. 中国冶金工业医学志, 2014, 31(1):4-6.
[26]	Htay H, Johnson DW, Wiggins KJ, et al. Biocompatible dialysis fluids for peritoneal dialysis[J]. Cochrane Database Syst Rev, 2018, 10(10): CD007554.
[27]	Campbell DJ, Johnson DW, Mudge DW, et al. Prevention of peritoneal dialysis-related infections[J]. Nephrol Dial Transplant, 2015, 30(9):1461-1472. doi: 10.1093/ndt/gfu313 URL

腹膜透析置管患者预防性应用抗生素的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黎恒楠, 黄艳, 赵亚娟, 胡桂才. 血清CTRP5与持续非卧床腹膜透析患者左室舒张功能异常的相关性及其诊断价值[J]. 临床荟萃, 2023, 38(4): 324-329.
[2]	史伟佳, 张晓宁, 刘雪宇, 曹延萍. 腹膜透析置管技术的最新研究进展[J]. 临床荟萃, 2023, 38(12): 1150-1152.
[3]	公智卿, 卢冬梅, 邢广群. 血清甲状旁腺激素水平结合控制营养状态评分对腹膜透析置管相关性腹膜炎发生预测及预后影响[J]. 临床荟萃, 2023, 38(11): 991-995.
[4]	张宏涛, 杨雨, 王志奎. 腹膜透析患者心力衰竭治疗药物研究进展[J]. 临床荟萃, 2022, 37(6): 556-559.
[5]	张宏涛, 王志奎. 单中心维持性腹膜透析患者肾性贫血现况及相关因素分析[J]. 临床荟萃, 2022, 37(12): 1099-1103.
[6]	公智卿, 陈怿鹏, 卢冬梅, 辛丽丽, 郭菁, 邢广群. 单糖特征分析在腹膜透析相关性腹膜炎病原菌诊断中的价值[J]. 临床荟萃, 2022, 37(11): 1012-1016.
[7]	程慧栋, 司博林, 华琴, 何建强, 桂兰兰. 腹膜透析导管徒手薅除术与手术切开拔管术的疗效对比[J]. 临床荟萃, 2021, 36(12): 1097-1101.
[8]	石友山, 陈天浩. 单中心腹膜透析相关性腹膜炎致病菌及病因分析[J]. 临床荟萃, 2020, 35(11): 1010-1014.
[9]	姚灿，王荣珍，刘天喜. 血清klotho蛋白、FGF23与腹膜透析患者营养状态相关性分析[J]. 临床荟萃, 2020, 35(10): 922-926.
[10]	司博林，申瑞芳，罗燕萍，余姝. 腹膜透析患者残肾功能对血管内皮细胞功能的影响[J]. 临床荟萃, 2017, 32(8): 691-694.
[11]	邹芸，周华. 腹膜透析患者并发脑卒中相关危险因素临床分析[J]. 临床荟萃, 2017, 32(5): 429-431,436.
[12]	赵霞，郭馨，王嵘，张东成. 生血宁治疗维持性腹膜透析患者的临床观察[J]. 临床荟萃, 2016, 31(9): 1015-1018.
[13]	童玉娜;龚蓉. 腹膜透析治疗与残余肾功能保护的研究进展[J]. 临床荟萃, 2014, 29(4): 465-468.
[14]	全大勇;龚蓉;皮婧静;舒英;杨斌;刘蔓莉;李迎春;叶娜. 不同透析模式对初始透析患者临床疗效及并发症分析[J]. 临床荟萃, 2014, 29(10): 1171-1174.
[15]	王爽;西桂杰;毛英丽;李亮;王文文. 腹膜透析治疗多脏器功能障碍综合征并高钠血症1例[J]. 临床荟萃, 2013, 28(9): 1055-1056.